A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.
Acute Myeloid Leukemia|Myelodysplastic Syndrome
DRUG: Co-ArgI-PEG modified human arginase I
Maximum Tolerated Dose and Recommended Phase 2 Dose, The dose level at which no more than 1/6 patients experiences dose-limiting toxicity, 4 weeks
Safety profile (changes in physical exam, laboratory measures, reported adverse events), changes in physical exam, laboratory measures, reported adverse events, 4 Weeks
This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.